Search Results 561-570 of 18378 for alopecia

1. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer - Mayo Clinic

   All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1; Patients who are ...

2. Dutasteride (oral route) - Side effects & dosage - Mayo Clinic

   Note: Women of childbearing potential should not use or handle dutasteride capsules. Dutasteride can cause birth defects in male fetuses. Dutasteride is used ...

3. A Study to Evaluate ION251 to Treat Patients with Relapsed/Refractory Multiple Myleoma - Mayo Clinic

   ... alopecia, fatigue, erectile dysfunction, hot flashes, cough, and urinary incontinence). Termination from prior line of multiple myeloma therapy at least 14 ...

4. A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer - Mayo Clinic

   ... alopecia, radiation tissue fibrosis, or peripheral neuropathy) * Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients and ...

5. Study Of Chemotherapy Plus Ipatasertib For People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial - Mayo Clinic

   therapy, except alopecia within 14 days prior to registration - Participants with neuropathy must have resolved to < grade 2 within 14 days prior to

6. A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the effects of prior chemotherapy (except for alopecia) regardless of the interval since last ...

7. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Adverse events from prior anti-cancer therapy resolved to ≤Grade 1 (with the exception of alopecia and anorexia). Exclusion Criteria for Phase II Portion ...

8. A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   Participants with diabetes Type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

9. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

   ... alopecia) prior to initiation of study drug administration; Adequate hematologic and organ function as confirmed by laboratory values; Last dose of any prior ...

10. A Study to Evaluate Lasofoxifene versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer Patients with an ESR1 Mutation - Mayo Clinic

    Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry. ECOG performance score of ...